Health
CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…
-
Business19 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News20 hours agoBroncos staffer who guided Mam through crash crisis admits to drink-driving
-
Noosa News21 hours agoQueenslanders to continue legal challenges against COVID-19 directives after successful appeal
-
Noosa News14 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track